

# Genetic/Environmental Contributions and Immune Dysregulation in Children with Atopic Dermatitis

Albert C Chong <sup>1</sup>, Kittipos Visitsunthorn<sup>2</sup>, Peck Y Ong <sup>1-3</sup>

<sup>1</sup>Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; <sup>2</sup>Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA; <sup>3</sup>Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles, Los Angeles, CA, USA

Correspondence: Peck Y Ong, Children's Hospital Los Angeles, Division of Clinical Immunology and Allergy, 4650 Sunset Blvd., MS #75, Los Angeles, CA, 90027, USA, Tel +1323 361-2501, Email pyong@chla.usc.edu

**Abstract:** Atopic dermatitis (AD) is one of the most common skin conditions in humans. AD affects up to 20% of children worldwide and results in morbidity for both patients and their caregivers. The basis of AD is an interplay between genetics and the environment characterized by immune dysregulation. A myriad of mutations that compromise the skin barrier and/or immune function have been linked to AD. Of these, filaggrin gene (*FLG*) mutations are the most evidenced. Many other mutations have been implicated in isolated studies that are often unreplicated, creating an archive of genes with potential but unconfirmed relevance to AD. Harnessing big data, polygenic risk scores (PRSs) and genome-wide association studies (GWAS) may provide a more practical strategy for identifying the genetic signatures of AD. Epigenetics may also play a role. *Staphylococcus aureus* is the most evidenced microbial contributor to AD. Cutaneous dysbiosis may result in over-colonization by pathogenic strains and aberrant skin immunity and inflammation. Aeroallergens, air pollution, and climate are other key environmental contributors to AD. The right climate and/or commensals may improve AD for some patients.

**Keywords:** atopic dermatitis, genetics, environment, pollution

## Introduction

AD is one of the most common skin conditions, affecting up to 20% of children worldwide.<sup>1</sup> It is characterized by a chronic relapsing pruritic rash appearing in an age-dependent distribution and is often associated with elevated immunoglobulin (Ig)E, peripheral eosinophilia, and other allergic diseases.<sup>2</sup> AD results in significant impact on children's quality of life due to itching, scratching, emotional distress, and sleep disturbance.<sup>3</sup> The median annual out-of-pocket expense for AD in the United States (US) is 600 US dollars (USD) and may be 1000 USD or greater for over 40% of patients and families.<sup>4</sup>

Children with AD may suffer a wide range of allergic, psychological, and infectious comorbidities. Classically, AD has been linked to asthma and allergic rhinitis (AR) in the "atopic march", a hypothesized progression of diseases from AD to respiratory allergies.<sup>5</sup> However, while atopic diseases do commonly co-occur, most do not follow this temporality.<sup>5,6</sup> The Childhood Origin of ASThma study, a high-risk birth cohort study, has shown that the early/recurrent phenotype of AD (presents early and persists through childhood) is associated with food allergy and both the early/recurrent phenotype and late-onset phenotype (AD starting at four- to six-years-old) are associated with asthma in children.<sup>7</sup> Notably, atopic comorbidity may be a feature of pediatric AD and less common in adult-onset AD.<sup>8,9</sup> Besides allergic comorbidities, children with AD show increased risks of having anxiety and attention-deficit hyperactivity disorder as well as certain bacterial and viral infections.<sup>10,11</sup> The consequences of AD extend to caregivers, who suffer mental and physical health effects tied to the quality of life of these children.<sup>3,12,13</sup>


AD is a disease of defective genetics in an unfavorable environment. Its underlying mechanisms are largely based in immune dysregulation. Notably, there may be pathophysiological differences between AD in children and adults. Regarding the skin barrier, pediatric AD has more *FLG* loss-of-function (LoF) variants and lipid-barrier defects, while adult AD shows more epidermal differentiation and cornification defects.<sup>6</sup> Regarding immune dysregulation, pediatric AD shows the highest skin eosinophil and neutrophil counts and greater induction of T-helper (Th)2, Th9, Th17, interleukin (IL)31, IL33, and innate immune markers; meanwhile, adult AD is skewed towards Th1 activation.<sup>6,9,14,15</sup> In both children and adults, AD skin is likely predisposed to pathogen colonization, which may contribute to disease progression.<sup>16</sup> Pediatric AD not only predisposes to skin infections but also increases allergen sensitization, including to food and aeroallergens.<sup>17</sup> Taken together, in pediatric AD, microbes, aeroallergens, and pollutants may penetrate the inherently defective skin barrier to trigger dysregulation of the immune system (which may itself be predisposed by genetic defects), causing further skin damage, chronic inflammation, and itch; notably, the right climate and/or commensals may improve some AD<sup>18,19</sup> [Figure 1]. This paper summarizes the current understanding of how genetics, environment, and immune system dysregulation drive AD in children.

## Genetic Contributions

### Skin Barrier Defects

AD skin shows decreased keratinocyte (KC) differentiation in the epidermis and is deficient in stratum corneum components including proteins (filaggrin, loricrin, involucrin, claudins) and lipids (ceramide, cholesterol, fatty acids).<sup>20</sup> Compared to healthy skin, AD skin shows reduced hydration and increased water loss as measured by trans-epidermal water loss (TEWL)<sup>21</sup> [Figure 1]. This holds true even when AD skin is normal-appearing. Supporting the role of a defective skin barrier in AD, TEWL is positively correlated with AD severity and may predict AD development.<sup>22,23</sup> The epidermal differentiation complex (EDC) is a 2 Mb region of human chromosome 1q21 that is the site of key genes for establishing the skin barrier (ie, *FLG*).<sup>24</sup> The EDC also controls epithelial tissue development and repair by regulating the terminal differentiation program of KC.<sup>25</sup> The EDC includes three gene families including the cornified envelope precursor family, the S100 protein family, and the S100 fused type proteins (SFTP).<sup>26</sup>

*FLG* is the most studied and implicated gene in AD and is a member of the SFTP family on the EDC. A *FLG* LoF mutation reduces skin hydration<sup>12</sup> [Figure 1]. Given that TEWL is increased in unaffected *FLG* mutation carriers, skin barrier impairment likely precedes clinical eczema.<sup>27</sup> *FLG* mutations occur in up to 50% of children with moderate to



**Figure 1** The interplay of genetic and environmental contributors in modulating the immune dysregulation of AD.

severe eczema, and the presence of *FLG* LoF variants in AD is significantly greater than in healthy controls.<sup>26,28</sup> The genetic configuration is likely a combination of common variants and rare LoF variants.<sup>28</sup> *FLG* LoF status appears to control the disease course of AD. Carrying a *FLG* LoF variant is associated with earlier disease onset among AD patients and increases the odds of onset before age 5- and 20-years-old by 7.8 and 8.9 times, respectively.<sup>26</sup> Certain *FLG* LoF mutations are associated with AD patients with a history of recurrent skin infections.<sup>29</sup> *FLG* mutations cause both barrier defects as well as altered hydration and pH of the stratum corneum, which may modulate the growth of *S. aureus*.<sup>20,30</sup> The *FLG* LoF mutation may also predispose to increased allergic sensitization<sup>31</sup> due to increased ability of allergens to penetrate into deeper skin layers. In addition to direct *FLG* mutations, Th2 cytokines IL4, IL13, and IL31 can suppress *FLG* expression and/or interfere with KC differentiation.<sup>32–35</sup>

While *FLG* has received the most attention, other EDC genes may be relevant in AD [Table 1]. A whole genome sequencing study showed enrichment of rare LoF variants of *FLG2*, *HRNR*, *LCE2C*, *LCE4A*, *LCE5A*, *RPTN*, *S100A3*, *S100A16*, *SPRR3*, *SPRR4*, *TCHH*, and *TCHHL1* in AD patients.<sup>26</sup> Expression of *FLG2* and *HRNR* are significantly reduced in both lesional and non-lesional skin of patients with AD compared with healthy subjects.<sup>36</sup> Upregulation of *S100A7* and *S100A8* and downregulation of *FLG* and the loricrin gene (*LOR*) has also been observed in AD and may represent abnormal epidermal differentiation and defective defenses favoring the alternative keratinization pathway.<sup>37</sup> Single nucleotide polymorphisms (SNPs) in *CLDN1* in AD may compromise tight junctions.<sup>38</sup> In fact, *CLDN1* is involved in the susceptibility to AD in the Ethiopian population.<sup>39</sup> Missense mutations in the Transmembrane Protein 79 (or Mattrin) gene (*Tmem79/matt*) may also predispose humans to AD.<sup>40</sup> In mice, mutations in the gene produce a dermatitis phenotype likely by disrupting the lamellar granule secretory system and altering stratum corneum barrier function.<sup>41</sup> *Tmem79/matt* has limited sequence homology to microsomal glutathione transferases and protects against reactive oxygen species.<sup>29</sup> Interestingly, mice with specific *Tmem79/matt* mutations developed IL17A-dependent

**Table 1** Potential Genetic Contributors to AD

Skin Barrier	Epidermal differentiation complex	<i>FLG</i> , <i>FLG2</i> , <i>HRNR</i> , <i>LCE2C</i> , <i>LCE4A</i> , <i>LCE5A</i> , <i>RPTN</i> , <i>S100A3</i> , <i>S100A7</i> , <i>S100A8</i> , <i>S100A16</i> , <i>SPRR3</i> , <i>SPRR4</i> , <i>TCHH</i> , <i>TCHHL1</i> , <i>CLDN1</i> , <i>Tmem79/matt</i> , <i>LELPI</i>
	SP and SP inhibition	<i>SERPINB7</i> , <i>KLK7</i>
	Desmosome component	<i>DSCI</i>
	Epigenetics	<i>KIF3A</i> methylation, <i>PPAR<math>\delta</math></i> upregulation, <i>EMSY</i> upregulation
Immune System		
	Innate immunity	<i>TLR2</i> , <i>TLR4</i> , <i>TLR9</i> , <i>NOD1</i> , <i>NOD2</i> , <i>DEF<math>\beta</math>1</i> , <i>IFN<math>\gamma</math></i> , <i>IFN<math>\gamma</math>R</i> , <i>IRF2</i> , <i>SIDT2</i> , <i>RBBP8NL</i>
	Cytokine-related	<i>IL4/4R</i> , <i>IL5</i> , <i>IL7R</i> , <i>IL9</i> , <i>IL10</i> , <i>IL12</i> , <i>IL13</i> , <i>IL18</i> , <i>IL31</i> , <i>TSLP</i> , <i>STAT6</i>
	Antigen receptor signaling	<i>CARD14</i> , <i>LRRC32</i>
	IgE-related	<i>Fc<math>\epsilon</math>RI<math>\beta</math></i> , <i>ADAMTSL4</i>
	Leukotriene-related	<i>CYSLTR1</i>
	Epigenetics	<i>AHR</i> upregulation, reduced <i>IL13</i> methylation, reduced <i>Ach3K9</i> acetylation

**Note:** Gene names are italicized.

dermatitis and were refractory to *S. aureus* infection.<sup>42</sup> Certain genetic variants of *LELPI* have been associated with elevated IgE levels, early-onset, house dust mite (HDM) sensitization, and disease severity in AD.<sup>43</sup>

Beyond the EDC, aberrant epidermal serum protease (SP) activity and desmosome instability may contribute to the skin barrier defects of AD [Table 1]. *SERPINB7* and *DSCI* code for a SP inhibitor and desmosome component, respectively, and missense mutations of these genes have been linked to AD via GWAS.<sup>44</sup> Meanwhile, AACC insertion in the SP gene *KLK7* has also been associated with AD,<sup>45</sup> introducing the potential relevance of direct SP mutations.

Epigenetics may contribute to the defective skin barrier of AD [Table 1]. For example, highly methylated *KIF3A* SNPs are associated with a decreased expression of KIF3A barrier protein in epithelial cells, leading to an increase in TEWL and risk of AD.<sup>46</sup> Meanwhile, transcription factor PPAR $\delta$ , which regulates inflammation and promotes KC proliferation and differentiation, is upregulated in lesional AD skin versus non-lesional skin.<sup>45,47,48</sup> FABP5, a fatty acid-binding protein expressed in the epidermis, delivers ligands to PPAR $\delta$  in keratocyte nuclei to enhance transcription.<sup>49</sup> Supporting this mechanism, *PPAR $\delta$*  and *FABP5* expressions parallel each other in AD.<sup>45,50</sup> Recently, GWAS has implicated *EMSY*, a transcriptional regulator supporting skin barrier formation.<sup>51</sup>

## Immune System Defects and Dysregulation

Regarding the innate immune system, stimulated KCs from AD patients produce diminished levels of antimicrobial peptides (AMPs) versus healthy subjects and those with psoriasis,<sup>52</sup> another chronic skin condition with barrier defects. Pattern recognition receptor (PRR) defects may mediate this phenomenon. For example, genetic polymorphisms in toll-like-receptors (TLRs) make AD skin vulnerable to infections.<sup>35</sup> TLR2 is a key PRR for *S. aureus*, and *TLR2* polymorphisms are linked to severe AD with recurrent skin infections.<sup>53,54</sup> Overall, AD patients show diminished responses upon TLR2 stimulation including reduced IL6, IL8, CCL20 and MMP9 production, which may predispose to infections.<sup>55</sup> However, monocytes with *TLR2* heterozygous R753Q polymorphism showed higher production of IL6 and IL12 versus those with non-mutated *TLR2*. This mutation is found more frequently in Italian children with severe AD but not in Turkish AD children.<sup>55–57</sup> *TLR2* mutations are especially interesting, as TLR2 may mediate transformation of acute to chronic AD via IL4-mediated suppression of IL10.<sup>58</sup> Other PRR mutations have also been linked to AD. The *TLR4* 896G mutation may be associated with a severe AD course, while *TLR9* promoter polymorphisms have been associated with impaired immunity in some cases of AD.<sup>59,60</sup> *NOD1* and *NOD2* encode PRRs for sensing viral/parasitic infections and perceiving perturbations of cellular processes such as regulation of the actin cytoskeleton and maintenance of endoplasmic reticulum homeostasis,<sup>61</sup> variants in these genes have been associated with AD.<sup>62,63</sup>

Besides PRRs, other components of innate immunity may be involved<sup>45,64</sup> [Table 1]. Human beta defensins (h $\beta$ Ds) provide antimicrobial and immunomodulatory benefits and are relevant to the genetics of AD.<sup>65</sup> h $\beta$ D2 and h $\beta$ D3 are produced at low levels in lesional skin of patients with AD relative to patients with psoriasis.<sup>66,67</sup> Furthermore, patients with AD complicated by eczema herpeticum (EH) have reduced h $\beta$ D2 and h $\beta$ D3 in lesional skin relative to patients with AD or psoriasis.<sup>68</sup> *DEFB1* SNPs are significantly associated with susceptibility to AD in Koreans.<sup>69</sup> However, they are not associated with AD in children and adolescents from northeast Brazil.<sup>70</sup> *IFN* and *IFN* receptor gene (*IFNR*) variants are associated with AD patients with a history of EH; transcripts for *IFN $\gamma$*  and *IFNRs* ( $\alpha$ ,  $\beta$ ,  $\omega$ ,  $\gamma$ ) are downregulated in these patients.<sup>20,71,72</sup> Specifically, mutations in *IFN $\gamma$*  and the *IFN $\gamma$ R* may occur in AD patients with EH history versus those without EH history.<sup>20</sup> IRF2 blocks the IFN $\gamma$ -mediated pathway, and different variants of *IRF2* are associated with Caucasian American and African American AD patients with a history of EH.<sup>73</sup> Recently, whole genome sequencing has identified *SIDT2* and *RBBP8NL* variants in AD; these genes participate in defense against herpes simplex virus (HSV)1.<sup>74</sup>

Classically, AD lesions are characterized by an increased expression of Th2 cytokines, which have been implicated in tissue repair.<sup>75</sup> Indeed, cytokine-related genes represent a sizeable group of potential offender genes whose variants have been associated with AD<sup>35,64,76,77</sup> [Table 1]. As a result of inherent barrier defects such as *FLG* mutations or lipid deficiencies, there is an overproduction of Th2 cytokines (classically IL4, IL13, and IL31) in the skin lesions of predisposed individuals [Figure 1]. IL4 activation of signal transducers and activators of transcription (STAT)6 results in Th2-deviated T cell differentiation, IgE production in B cells, and the production of Th2 chemokines such as CCL17 and CCL22 by dendritic cells (DCs). Th2 cytokines may in turn downregulate *FLG*, *LOR*, and involucrin gene (*IVL*) expression and reduce AMP production, further compromising the skin barrier and increasing susceptibility to pathogens.<sup>78</sup> 590T and 589T alleles of *IL4* may be associated with high serum IL4 levels, which appear to increase the risk of AD in children.<sup>79</sup> *IL13* Arg130Gln polymorphism and haplotypes consisting of *IL13*

Arg130Gln and *IL4*-589C/T are linked to development of atopy and AD.<sup>80</sup> *IL31* causes pruritus, and *IL31* variants are associated with AD and its severity.<sup>81,82</sup> Janus kinase (JAK)1 and JAK2 are tyrosine kinases involved in the JAK-STAT pathway that direct inflammation via cytokines (including *IL4*, *IL13*, *IL31*) and IFN signal transduction.<sup>76,83</sup> Thymic stromal lymphopoietin (TSLP) activates dermal DCs to recruit Th2 cells that release *IL4* and *IL13*.<sup>84-87</sup> TSLP also activates type 2 innate lymphoid cells, which express *IL4*, *IL5*, and *IL13*. Furthermore, TSLP may cause pruritus by activating cutaneous sensory neurons. SNPs in *TSLP* and its receptor component *IL7R* may modulate AD persistence.<sup>88,89</sup> *TSLP* SNPs are also associated with EH.<sup>90</sup> Interestingly, while *STAT6* mediates *IL4/IL13* activation of Type 2 inflammation,<sup>91</sup> it may also work with another transcription factor T-bet to suppress skin inflammation by inhibiting TSLP-dependent *IL9* production in CD4+ T cells of mice.<sup>92</sup> *STAT6* genetic variants are associated with AD patients with a history of EH and are known to increase viral replication in the skin of these patients.<sup>93</sup>

Several other categories of immune genes have been implicated in AD including antigen receptor signaling (*CARD14*, *LRRC32*), IgE-related (*FcεRIβ*, *ADAMTSL4*), and leukotriene-related (*CYSLTR1*) genes<sup>76,94,95</sup> [Table 1]. *CARD14* mediates production of proinflammatory genes and AMPs via activation of the nuclear factor-κB (NF-κB) pathway.<sup>96,97</sup> Interestingly, while a dominant gain-of-function (GoF) mutation in *CARD14* occurs in psoriasis, a LoF mutation in this gene accompanies severe AD.<sup>98</sup> *LRRC32* (also known as *GARP*) encodes GARP, a cell surface receptor on Treg cells, platelets, and certain cancer cells.<sup>99</sup> GARP may inhibit Treg immunosuppressive activity.<sup>100</sup> Recently, polymorphisms in *LRRC32* have also been linked to AR.<sup>101</sup> IgE-mediated inflammation may also contribute to AD.<sup>102</sup> *FcεRIβ* encodes a subunit of the high-affinity IgE receptor FcεRI and mediates trafficking and signaling of this receptor.<sup>103</sup> Meanwhile, *ADAMTSL4* encodes a potential IgE-binding self-antigen in AD and has been linked to eosinophil counts, which are known to be elevated in AD.<sup>104-106</sup> Finally, *CYSLTR1* encodes a receptor for cysteinyl leukotrienes; variants may predispose children to asthma and AD.<sup>107</sup>

Epigenetics may modulate the immune response of AD [Table 1]. There are significant differences in the DNA methylation levels between the skin-homing CD4+CLA+ T cells of AD patients compared to healthy controls.<sup>108</sup> Reduced methylation levels in the *IL13* gene in CD4+CLA+ T cells of AD patients are associated with an increased expression of *IL13* mRNA in these cells.<sup>108</sup> The transcription factor aryl hydrocarbon receptor gene (*AHR*) is upregulated in AD lesional skin versus normal skin in healthy controls.<sup>109</sup> Chronic AHR activation is immunotoxic<sup>110</sup> and results in expression of neurotrophic factor artemin, alopecia, epidermal hyper-innervation, and inflammation.<sup>111</sup> In mice, constitutive activation of AHR increases artemin and produces an AD phenotype including erosive facial and back eczema with frequent scratching.<sup>110-112</sup> AD epigenetics may also be modulated by microbial metabolites including butyric acid (BA), a fermentation product of *Staphylococcus epidermidis* that inhibits *S. aureus* growth.<sup>113,114</sup> In response to BA derivative BA-NH-NH-BA, human KCs increase acetylation of *Ach3K9*, which is accompanied by reduced *S. aureus*-induced production of proinflammatory *IL6* and *S. aureus* colonization in murine skin,<sup>115</sup> suggesting modulation of *S. aureus* pathogenicity through epigenetic mechanisms.

## Genetic Disorders with AD-Like Lesions

There are a number of genetic disorders including immunodeficiency, autoimmunity, and non-immune abnormalities that feature AD-like lesions. These conditions and their known culprit genes include Hyper IgE syndrome (*STAT3*, *DOCK8*), CARMIL2 deficiency (*CARMIL2*), Omenn syndrome (*RAG1*, *RAG2*), Netherton syndrome (*SPINK5*), Wiskott-Aldrich syndrome (*WAS*), adenosine deaminase severe combined immunodeficiency (ADA-SCID) (*ADA*), immune dysregulation, poly-endocrinopathy, enteropathy, X-linked (IPEX) syndrome (*FOXP3*), CARD11-associated atopy with dominant interference of NF-κB signaling (CADINS) disease (*CARD11*), congenital disorders of glycosylation (*PGM3*), prolidase deficiency (*PEPD*), severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome (*DSG1*, *DSP*), and growth hormone insensitivity (GHI) syndrome with immunodeficiency (*STAT5B*).<sup>116-129</sup> Recently, GoF *STAT6* variants have been associated with a novel autosomal dominant allergic disorder featuring early-onset allergic immune dysregulation with widespread refractory AD, hypereosinophilia with eosinophilic esophagitis, high serum IgE, food allergies, and brain vascular anomalies.<sup>130</sup> Although rare, these genetic disorders should be considered in the differential diagnosis of AD, especially in patients where the constellation of findings exceeds atopy. These findings include unresponsiveness to conventional AD treatments, unusual opportunistic infections, or symptoms of autoimmunity.<sup>131</sup> Understanding the basis of these genetic disorders may also provide insights into the mechanisms of AD.

The culprit genes for such conditions fall under several categories: cytokine-related (*STAT3*, *STAT5B*, *STAT6*, *FOXP3*), antigen receptor signaling (*CARD11*, *CARMIL2*, *ADA*, *RAG1*, *RAG2*), actin polymerization (*DOCK8*, *WAS*,



*CARMIL2*), cellular metabolism (*PGM3*), collagen metabolism (*PEPD*), SP inhibition (*SPINK5*), and desmosome components (*DSG1*, *DSP*) [Table 2]. STAT3 participates in Th2 differentiation<sup>132</sup> and KC STAT3 may mediate histaminergic itch.<sup>133</sup> STAT5B and STAT6 also mediate Type 2 inflammation and STAT5B additionally mediates growth hormone signaling.<sup>91,134</sup> FOXP3 suppresses the immune system through its influence on transcription factors including

**Table 2** Genetic Disorders with AD-Like Lesions and Their Implicated Genes

Hyper-IgE syndrome		
	Cytokine-related	<i>STAT3</i>
	Actin polymerization	<i>DOCK8</i>
CARMIL2 deficiency		
	Antigen receptor signaling, actin polymerization	<i>CARMIL2</i>
Omenn syndrome		
	Antigen receptor signaling	<i>RAG1</i> , <i>RAG2</i>
Netherton syndrome		
	SP inhibition	<i>SPINK5</i>
Wiskott-Aldrich syndrome		
	Actin polymerization	<i>WAS</i>
ADA-SCID		
	Antigen receptor signaling	<i>ADA</i>
IPEX syndrome		
	Cytokine-related	<i>FOXP3</i>
CADINS disease		
	Antigen receptor signaling	<i>CARD11</i>
Congenital disorders of glycosylation		
	Cellular metabolism	<i>PGM3</i>
Prolidase deficiency		
	Collagen metabolism	<i>PEPD</i>
SAM syndrome		
	Desmosome components	<i>DSG1</i> , <i>DSP</i>
GHI syndrome with immunodeficiency		
	Cytokine-related	<i>STAT5B</i>
Novel autosomal dominant allergic disorder		
	Cytokine-related	<i>STAT6</i>

**Note:** Gene names are italicized.

NF- $\kappa$ B.<sup>135</sup> CARMIL2 mediates NF- $\kappa$ B signaling and regulates actin polymerization in T cells; besides immunodeficiency, genetic variants have also been associated with inflammatory bowel disease in children.<sup>136</sup> ADA is part of the purine salvage pathway and plays a key role in B and T cell development; defects may cause mild AD.<sup>137,138</sup> RAG1 and RAG2 enable V(D)J recombination to produce diverse T and B cell receptors.<sup>139</sup> DOCK8 controls lymphocyte migration, survival, and effector functions through CDC42-mediated actin polymerization.<sup>140,141</sup> DOCK8 deficiency may cause Th2 polarization away from the Th1 and Th17 types, resulting in atopic disease and compromised immunity against viruses and fungi; the AA genotype of DOCK8 is linked to elevated total IgE levels.<sup>98,142</sup> WAS mediates actin cytoskeleton remodeling to enable immune functions including signal transduction, adhesion, movement, proliferation, and phagocytosis.<sup>143</sup> PGM3 is a phosphoglucomutase that metabolizes glycans, and deficiencies may impair cell-cell recognition and immune signaling.<sup>144</sup> *PEPD* encodes prolidase, which metabolizes proline-containing proteins including collagen.<sup>124</sup> *SPINK5* encodes the SP inhibitor LEKTI, thereby modulating skin desquamation.<sup>145,146</sup> Finally, *DSG1* and *DSP* encode desmosome components that contribute to epidermal structure and integrity.<sup>147</sup>

## Polygenic Risk Scores and Genome-Wide Association Studies

While a genetic basis to AD is clear, confirming the clinical relevance of specific genes in AD has proven challenging. The *FLG* LoF mutation is a special case, where mutations in a specific gene are known to compromise the AD skin barrier. The tendency is for studies to highlight one gene or another without reproduction in most cases. For example, no particular gene has been confirmed in the dysregulated immune response of AD. To bridge the gap between research and clinical utility, PRSs have been introduced and show promise for predicting AD. The PRS is a prediction of an individual's phenotype based on the individual's particular genetic variants weighted by their disease-specific effect sizes; disease-specific effect sizes are determined from external, independent GWAS. Recently, Arehart et al showed that AD PRSs track phenotypic outcome and correlate with AD severity.<sup>148</sup> Furthermore, incorporating genetic determinants across atopic phenotypes and *FLG* LoF variants into PRSs increased their predictive capacity, and this model was able to distinguish individuals with severe AD from control subjects with an odds ratio of 3.86 (95% CI, 2.77–5.36). The predictive potential of PRSs is expected to increase with larger, higher-quality GWAS databases and inclusion of non-genetic covariates into these models, as the environment is a key driver of AD.<sup>149</sup>

GWAS has identified two highly significant loci for AD representing the EDC (chromosome 1q21.3) and a region including *IL4* and *IL13* (chromosome 5q13.1).<sup>150</sup> Chromosome 11q13.5 is another locus that has been strongly linked to AD in GWAS among different ethnicities and suggests *LRRC32* and *EMSY* as possible players in AD.<sup>51,150</sup> Among Caucasian patients, Sliz et al identified 30 AD-associated loci including five novel loci.<sup>44</sup> Missense variants in *DSCI* and *SERPINB7* were identified at two of these new loci; these genes have key roles in epidermal strength and stability.<sup>44</sup> Recently, a GWAS meta-analysis identified 271 AD-associated genes including seven with strong evidence of association (*ADAMTSL4*, *FKBPL*, *SIPAI*, *PPT2*, *C1orf68*, *SLC2ARG*, and *TDRKH*).<sup>151</sup> Notably, AD has polygenic architecture and shares biology with asthma.<sup>44,151</sup> GWAS may also be used to identify relationships between AD and other diseases or lifestyle factors via comparative analysis or Mendelian randomization.<sup>150,151</sup> For example, opposing genetic mechanisms have been identified in AD versus psoriasis<sup>152</sup> and BMI has been shown to have a small causal effect on AD.<sup>153</sup> Current GWAS only account for less than 20% of AD heritability.<sup>154</sup> Future GWAS should include greater ethnic diversity and functional assessment of candidate genes.<sup>154</sup> Furthermore, gene-environment interaction studies for AD are currently scant.<sup>155</sup>

## Environmental Contributions

### Bacteria

Bacteria have a role in modulating AD and the evidence implicating *S. aureus* is strongest [Figure 1, Table 3]. In a meta-analysis of 95 observational studies, Totte et al found that *S. aureus* is present on 70% of AD lesions compared to statistically lower presence on non-lesional or healthy control skin.<sup>156</sup> The authors also noted that in lesional skin, disease severity is associated with increased prevalence of *S. aureus*. Meanwhile, Tauber et al showed an association between *S. aureus* density and AD presence and disease course severity in lesional and non-lesional skin.<sup>157</sup> Biofilm-generating

**Table 3** Potential Environmental Contributors to AD

Microbes		
	Bacteria	<i>S. aureus</i>
	Viruses	Herpes simplex virus, molluscum contagiosum virus, coxsackie virus, vaccinia virus
	Fungi	<i>Malassezia spp.</i>
Aeroallergens		
	Indoor allergens	House dust mite, pet dander, fur, cockroach, mold
	Outdoor allergens	Tree pollens, grass pollens, weed pollens
Air Pollution		
	Particulate matter	PM2.5, PM10
	Gaseous pollutants	Sulfur dioxide, nitrogen dioxide, carbon monoxide
Climate		
	Humidity	Low or very high humidity
	UV index	Low UV index
	Temperature	Low or very high temperature, high indoor heating days
	Precipitation	High precipitation
Food		
	Rare occurrence	Cow's milk, hen's egg
	Birch pollen-related	Apple, carrot, celery, hazelnut

**Note:** Bacterial and fungal genera and species are italicized.

*S. aureus* strains from anterior nares and lesional skin in AD patients have been associated with more severe AD and extent of biofilm formation positively correlates with lesional intensity.<sup>158–160</sup> Allen et al reported that biofilm formation plays a major role in the occlusion of eccrine sweat ducts, which leads to inflammation and pruritus. Patients with severe AD were colonized by strong biofilm producing *S. aureus* strains.<sup>161</sup> Biofilms enhance bacterial adhesion, providing immune evasion and protection from competitor microbial species.<sup>161,162</sup> MRSA may colonize 18.3–25% of pediatric AD patients and is more prevalent in moderate to severe AD versus mild AD.<sup>163–165</sup> Colonization of AD skin with MRSA predisposes to increased skin and soft tissue infections (SSTIs) compared to colonization with MSSA.<sup>166</sup>

Staphylococcal enterotoxins (superantigens) are the most-studied bacterial virulence factors in AD. They include classical (SEA, SEB, SED, TSST-1) and non-classical (SEE, SEG, SEQ) superantigens.<sup>20</sup> More than 80% *S. aureus* in AD produce these superantigens.<sup>167</sup> Superantigen-activated DCs stimulate Th2 cells to produce IL4, IL5, IL13, and IL31, leading to skin barrier disruption including decreased FLG production, suppressed AMP production, impaired KC differentiation, and pruritus.<sup>168,169</sup> Moreover, specific IgE (sIgE) directed at superantigens leads to basophil histamine release.<sup>6</sup> MRSA produces more superantigen than MSSA<sup>170</sup> and superantigens may cause corticosteroid resistance in AD flares associated with MRSA skin infections.<sup>171</sup> *S. aureus* also produces alpha toxin that causes KC cytotoxicity, lymphocyte apoptosis, and alters E-cadherin integrity.<sup>168,172,173</sup> FLG deficiency and expression of *IL4* and *IL13* in AD enhance cytotoxicity of alpha toxin to KCs.<sup>174,175</sup> Delta toxin increases mast cell degranulation via MRGPRX2; notably, MRGPRX2 is also found on KCs.<sup>176,177</sup> Staphylococcal protein A blocks formation of IgG hexamers and downstream



activation of complement.<sup>178</sup> Finally, lipoteichoic acid (LTA) is a staphylococcal virulence factor that may activate TLR2 to convert acute AD into chronic AD.<sup>58</sup>

Cutaneous dysbiosis may be a key driver of AD. Microbiome diversity decreases in lesional AD skin with specific reduction in *Streptococcus*, *Corynebacterium*, *Propionibacterium*, and favoring *Staphylococcus*.<sup>114</sup> The microbiome composition returns to normal diversity after treatment, suggesting that treating AD supports the re-establishment of a normal microbiome. Commensals may counter *S. aureus* and support a healthy skin barrier and immunity [Figure 1]. For example, coagulase-negative Staphylococci (CoNS) (*S. epidermidis*, *S. hominis*, and *S. lugdunensis*) can produce AMPs that inhibit *S. aureus* growth.<sup>179–181</sup> CoNS strains with antimicrobial activity are deficient in AD versus healthy skin and reintroducing these strains may decrease *S. aureus* burden.<sup>180</sup> Indeed, *S. hominis* transplantation may improve local eczema severity by killing *S. aureus*.<sup>19</sup> Other commensals such as *Roseomonas*, *Corynebacterium*, and *Propionibacterium* have also been shown to affect *S. aureus* growth and virulence.<sup>182–185</sup> Normal microflora may promote healthy skin in diverse ways. *S. epidermidis* may shape cutaneous T cell populations to promote tolerance of commensals, immunogenicity against pathogens, and cutaneous wound repair.<sup>186,187</sup> Independent of T cells, LTA in the *S. epidermidis* cell wall may temper inflammatory responses to injury via TLR2.<sup>188</sup> Finally, *S. epidermidis* may curb skin inflammation through BA-mediated epigenetic mechanisms.<sup>115,189</sup>

## Viruses

Viral diseases including EH, molluscum contagiosum (MC), eczema coxsackium (EC), and eczema vaccinatum (EV) may afflict AD patients, yet whether viral infections lead to worsening of AD requires further study [Figure 1, Table 3]. AD patients are at increased risk of EH, which is caused by HSV.<sup>11</sup> Nearly a third of pediatric hospitalizations for AD infectious complications are related to EH.<sup>190</sup> Interestingly, EH is associated with AD flares and is more often a reactivation of HSV as opposed to a primary infection.<sup>191,192</sup> In AD patients, a history of skin infections with *S. aureus* is a risk factor for development of EH, and alpha toxin increases HSV load in KCs.<sup>72,193</sup> Meanwhile, downregulation of IFNs and their receptors also contribute to EH susceptibility as discussed previously. MC spreads by autoinoculation in AD patients due to scratching. *FLG* mutations have been linked to increased risk of sustained MC skin infection.<sup>194</sup> Furthermore, a history of AD has been reported in over a third of cases of MC in pediatric dermatology and appears to intensify the course of MC.<sup>195</sup> EC may appear similar to EH, and a lesional polymerase chain reaction for enterovirus may help differentiate between the two etiologies. Unlike EH, EC is not typically life-threatening and can be managed with skin hydration, moisturization, and topical corticosteroids (TCS).<sup>196</sup> EV is caused by vaccinia virus (VV) in smallpox vaccines and presents as a rapidly developing, generalized vesiculopustular rash that is life-threatening.<sup>197</sup> Given the recent monkeypox outbreaks across the globe, smallpox vaccines have seen renewed use as they provide some cross-protection for monkeypox.<sup>198,199</sup> Susceptibility to EV may be mediated by defects in IFN $\gamma$  or its receptor and increases in IL4, IL13, and IL17.<sup>200–202</sup> Clinicians should be advised that the ACAM2000 (replication-competent VV) is contraindicated in AD patients due to the risk of EV, but the Jynneos (replication-deficient Modified vaccinia Ankara) vaccine is safe for AD patients including those with human immunodeficiency virus.<sup>203</sup>

## Fungi

Further research is needed to evaluate fungi as potential contributors to AD [Figure 1]. *Malassezia spp.* are common commensals on human skin that may contribute to AD [Table 3]. While not life-threatening, *Malassezia spp.* are thought to enhance AD skin inflammation by eliciting IgE production and activating auto-reactive T cells.<sup>204</sup> The relative cutaneous abundance of *Malassezia spp.* differ by AD severity; for example, *M. restricta* predominates over *M. globosa* in mild or moderate AD while these species are more equally represented in severe disease.<sup>205,206</sup> AD appears to increase sensitization to *Malassezia spp.*, yet sensitization occurs preferentially in adults.<sup>204</sup> Specifically, *Malassezia spp.* sIgE are found in 5–27% of pediatric and 29–65% of adult AD patients,<sup>204</sup> although testing for *Malassezia spp.* sIgE is not standard practice. Interestingly, non-*Malassezia* yeast are more diverse in AD patients versus healthy individuals.<sup>207</sup> While topical ketoconazole has been observed to improve head and neck AD in some patients, a placebo-controlled trial found no difference between topical miconazole-hydrocortisone cream and ketoconazole shampoo versus hydrocortisone alone for head and neck AD.<sup>208</sup>

## Aeroallergens

Aeroallergens are recently established triggers of AD and produce cutaneous reactions likely through direct skin contact<sup>209,210</sup> [Figure 1]. Triggers include indoor aeroallergens (ie, HDM, pet dander, fur, cockroach, and mold) and outdoor aeroallergens (ie, tree, grass, and weed pollens) [Table 3]. Sensitization to HDM is particularly common in pediatric AD patients (48.9%) and children with a strong skin prick test (SPT) reaction to HDM have greater AD severity.<sup>211</sup> Upon penetrating the defective skin barrier, allergens may be presented in an IgE-facilitated or IgE-independent manner to T cells with subsequent release of Th2 cytokines IL4, IL13, and IL31 and downstream effects of B cell maturation to plasma cells and pruritus.<sup>210</sup> Alternatively, allergens may directly trigger neurons to release substance P and degranulate skin mast cells via the MRGPRX2 receptor.<sup>212,213</sup> Recently, propyl-paraben exposure has been linked with aeroallergen sensitization and AD severity.<sup>214</sup> Notably, sensitization to specific aeroallergens such as birch pollen may mediate late eczematous reactions to related foods.<sup>215</sup> A late reaction to melons in ragweed pollen sensitization has also been observed.<sup>216</sup>

Epicutaneous skin testing (ie, SPT) or serum sIgE testing may diagnose aeroallergen sensitivities. sIgE testing is an option for patients with dermatographia or widespread AD. While guidelines do not recommend routine testing for aeroallergens in AD, testing should be considered in patients in whom aeroallergen triggers are suspected.<sup>217</sup> Currently, management centers on avoidance and maintenance of the skin barrier.<sup>210</sup> Avoidance includes removing pets or keeping them in another room, implementing dust mite-proof pillow or mattress encasings, and wearing occlusive clothing outdoors. Skin moisturization and TCS for flares are recommended to restore and maintain the skin barrier. Subcutaneous immunotherapy (SCIT) has been shown to improve AD in patients sensitized to HDM and decreases the need for topical corticosteroids.<sup>218</sup> Meanwhile, sublingual immunotherapy (SLIT) to HDM has been shown to improve mild, moderate, and severe AD.<sup>219,220</sup> While SCIT and SLIT have shown promise, they are not yet indicated for the management of AD at this time.

## Air Pollution

Air pollution is an increasingly recognized contributor to AD [Figure 1, Table 3]. A recent study found that short-term exposure to air pollution secondary to a California wildfire was associated with increased health-care use for patients with AD and itch.<sup>221</sup> Increases were seen in pediatric appointments for both AD and itch. Specifically, a 10- $\mu\text{g}/\text{m}^3$  increase in weekly mean particulate matter  $\leq 2.5$   $\mu\text{m}$  in diameter (PM<sub>2.5</sub>) concentration was associated with a 7.7% increase in weekly pediatric itch clinic visits. Meanwhile, long-term exposure to air pollutants has been shown to increase the development of AD.<sup>222</sup> These pollutants include PM<sub>2.5</sub>, particulate matter  $\leq 10$   $\mu\text{m}$  in diameter (PM<sub>10</sub>), sulfur dioxide, nitrogen dioxide, and carbon monoxide. Notably, younger AD patients (age zero- to seven-years-old) may be most susceptible to air pollutants.<sup>223</sup> In a systematic review and meta-analysis, pediatric AD was also associated with active and passive smoking, with odds ratios of 2.19 (1.34–3.57) and 1.15 (1.01–1.30), respectively.<sup>224</sup> However, smoke exposure may not trigger AD since cohort studies showed a lack of association between AD and passive smoking or maternal smoking during pregnancy.<sup>224</sup> Regarding a mechanism for air pollution-induced AD, PM contains polycyclic hydrocarbons (PAHs) that may activate AHR.<sup>225</sup> In fact, treatment of human skin equivalents and murine skin with PM<sub>2.5</sub> inhibits FLG protein expression via PM<sub>2.5</sub>-induced TNF- $\alpha$  and is AHR-dependent.<sup>226</sup> As discussed above, AHR activation may also increase artemin expression and itch. Finally, PM<sub>10</sub> exposure has been shown to induce/aggravate dermatitis in an AD mouse-model via the differential expression of genes controlling skin barrier integrity and the immune response.<sup>227</sup>

## Climate

Climate including humidity, UV index, temperature, and precipitation influences the prevalence of pediatric AD [Table 3]. Higher humidity, UV index, and temperature are associated with decreased AD prevalence.<sup>228</sup> However, overly high humidity or temperatures can cause perspiration, which may trigger AD in some patients.<sup>229</sup> Higher indoor heating days (a measure of the coldness of weather experienced) and precipitation are associated with increased AD prevalence.<sup>228</sup> Humidity may improve AD by compensating for increased TEWL.<sup>229</sup> Meanwhile, sub-thermogenic UV

light has been shown to reduce skin inflammation and may also reduce pruritus by direct or indirect effects on cutaneous sensory nerve fibers.<sup>230</sup> It is possible that a subset of mild AD patients may benefit from the right amount of humidity and UV exposure at the right (moderate) temperature [Figure 1]. While cohort studies of children in Europe have observed *FLG* LoF mutation frequencies of 15.1–20.9% and 5.8–13.0% in AD and non-AD groups, respectively,<sup>231–236</sup> Sasaki et al found no difference in *FLG* LoF mutation frequency between children with and without AD on a subtropical Ishigaki Island where humidity (monthly average, 60.8–78.7%) and temperature (monthly average, 18.5–29.4 °C) are elevated throughout the year.<sup>18</sup> While this is an interesting suggestion that a genetic predisposition to AD may be abrogated by a beneficial environment in some patients, future randomized controlled trials are required to further assess the potential benefits of climate on AD.

## Food

Ingestion of certain foods may exacerbate AD in select patients. Although rarely the cause, cow's milk and hen's egg are the most reported food triggers for AD in younger children.<sup>217</sup> Pollen-related food allergies may be considered in older children and adults.<sup>215,217</sup> Notably, avoidance of food is not indicated in management of most AD.<sup>237</sup> It is not uncommon that patients or providers incorrectly suspect diet as the cause of AD and inaccurately assign food allergies; this not only results in inappropriate testing and dietary changes but may also result in neglect of established AD treatments and possibly even development of IgE-mediated food allergy.<sup>237,238</sup> However, it is important for clinicians to be aware that the prevalence of food allergy is significantly higher in children with AD, as compared to healthy children. Therefore, timely prevention and proper diagnosis of food allergy in this population is warranted. While breastfeeding undoubtedly confers multiple physiological and psychological benefits to both mothers and children, the protective effect of breastfeeding against development of AD remains uncertain.<sup>239</sup>

## Conclusion

The pathogenesis of AD involves genetic and environmental triggers and is marked by immune dysregulation. From a genetics standpoint, mutations result in skin barrier defects (ie, EDC, SP/SP inhibition, desmosome component variants) and immune system defects (ie, innate immunity, cytokine-related, antigen receptor signaling, IgE-related, and leukotriene-related variants) and dysregulation. Epigenetics may modulate the immune disarray. As the vast complexity of AD genetics is now apparent, we look to PRSs and GWAS for more comprehensive genetic signatures of AD. From an environmental standpoint, microbes (ie, *S. aureus*), aeroallergens (ie, HDM and pollens), air pollution (ie, PM2.5), and climate (ie, humidity, temperature, UV index, precipitation) are key contributors. Cutaneous dysbiosis may modulate AD by increasing susceptibility to *S. aureus* and fostering abnormal skin immunity and inflammation. Meanwhile, the right climate and/or commensals may improve AD for some patients. While food may trigger AD in a small subset of patients, we caution against excessive dietary avoidance and recommend prioritization of AD management fundamentals.

Identification of AD offender genes and research into the dysregulated immune pathways has enabled the rapid expansion of precision medicine-based therapies.<sup>77</sup> Dupilumab is an anti-IL4 receptor antibody that interferes with IL4 and IL13 signaling and is approved for AD.<sup>240</sup> It may also improve AD related to *IL4/4R*, *IL13*, *DOCK8*, *CARD11*, *STAT3*, *SPINK5*, *ERBB2IP*, and *ZNF341* dysregulation.<sup>241–248</sup> Tralokinumab targets IL13 and is approved for moderate to severe AD in adults.<sup>77</sup> Topical ruxolitinib and oral upadacitinib, abrocitinib, and baricitinib (approved in Europe and Japan) are JAK inhibitors indicated for AD.<sup>249,250</sup> Topical PDE4 inhibitor crisaborole is also approved for AD patients down to three months of age.<sup>76</sup> Other biologics under study in the US include lebrikizumab, nemolizumab, and tezepelumab, which block IL13, IL31 receptor, and TSLP, respectively.<sup>76,251–253</sup> At the epigenetic level, topical tapinarof is approved for psoriasis and is being studied for use in AD. Tapinarof may outcompete toxicogenic ligands for AHR binding, resulting in downregulation of proinflammatory cytokines and normalization of the skin barrier.<sup>225,254,255</sup> Meanwhile, increasing recognition of the role of the microbiome in AD may lead to new therapies to re-balance pathogens and commensals on the skin. Cutaneous microbial transplantation and vaccines against *S. aureus* are two nascent strategies.<sup>256,257</sup> Randomized controlled trials are also needed to evaluate climate as a modulator of AD.

Explaining the genetic basis of AD to patients and families may improve compliance with moisturizers and topical anti-inflammatory medications based on their understanding that AD patients are inherently predisposed to skin barrier defects and cutaneous inflammation. Meanwhile, minimizing environmental triggers may lead to optimization of topical anti-inflammatory treatments and prevent the need for systemic therapy. Further studies in genetics and environmental triggers may lead to better AD treatments and possibly prevention of AD.

## Acknowledgments

We thank Chester Hui, BS for his assistance with proofreading the manuscript and tables. Dr. Ong is supported in part by the Albert and Bettie Sacchi Foundation.

## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

There is no funding to report.

## Disclosure

PYO reports consultant: Incyte, Abbvie, Janssen; research funding: Regeneron, Sanofi Genzyme, Leo, Incyte. The authors report no other conflicts of interest in this work.

## References

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. *Ann Nutr Metab.* 2015;66(Suppl 1):8–16. doi:10.1159/000370220
2. Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. *Immunol Allergy Clin North Am.* 2015;35(1):161–183. doi:10.1016/j.iac.2014.09.008
3. Xu X, van Galen LS, Koh MJA, et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study. *Sci Rep.* 2019;9(1):15990. doi:10.1038/s41598-019-51129-5
4. Smith begolka W, Chovatiya R, Thibau IJ, Silverberg JI. Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States. *Dermatitis.* 2021;32(1S):S62–S70. doi:10.1097/DER.0000000000000715
5. Busse WW. The atopic march: fact or folklore? *Ann Allergy Asthma Immunol.* 2018;120(2):116–118. doi:10.1016/j.anai.2017.10.029
6. Ramirez-Marin HA, Singh AM, Ong PY, Silverberg JI. Food allergy testing in atopic dermatitis. *JAAD Int.* 2022;9:50–56. doi:10.1016/j.jdin.2022.08.004
7. Singh AM, Evans MD, Gangnon R, et al. Expression patterns of atopic eczema and respiratory illnesses in a high-risk birth cohort. *J Allergy Clin Immunol.* 2010;125(2):491–493 e494. doi:10.1016/j.jaci.2009.11.026
8. Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. *J Am Acad Dermatol.* 2019;80(6):1526–1532 e1527. doi:10.1016/j.jaad.2018.05.1241
9. Vakharia PP, Silverberg JI. Adult-onset atopic dermatitis: characteristics and management. *Am J Clin Dermatol.* 2019;20(6):771–779. doi:10.1007/s40257-019-00453-7
10. Huang AH, Roh YS, Sutaria N, et al. Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States. *J Am Acad Dermatol.* 2021;85(4):893–900. doi:10.1016/j.jaad.2021.03.016
11. Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections. *Dermatitis.* 2020;31(2):157–164. doi:10.1097/DER.0000000000000526
12. Capozza K, Gadd H, Kelley K, Russell S, Shi V, Schwartz A. Insights from caregivers on the impact of pediatric atopic dermatitis on families: “I’m tired, overwhelmed, and feel like I’m failing as a mother”. *Dermatitis.* 2020;31(3):223–227. doi:10.1097/DER.0000000000000582
13. Kim RW, Barta K, Begolka WS, et al. Qualitative analysis of the impact of atopic dermatitis on caregivers. *Br J Dermatol.* 2022. doi:10.1111/bjd.21828
14. Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. *J Allergy Clin Immunol.* 2016;138(6):1639–1651. doi:10.1016/j.jaci.2016.07.013
15. Nygaard U, Hvid M, Johansen C, et al. TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. *J Eur Acad Dermatol Venereol.* 2016;30(11):1930–1938. doi:10.1111/jdv.13679
16. Shi B, Bangayan NJ, Curd E, et al. The skin microbiome is different in pediatric versus adult atopic dermatitis. *J Allergy Clin Immunol.* 2016;138(4):1233–1236. doi:10.1016/j.jaci.2016.04.053
17. Kroner JW, Baatyrbek Kyzy A, Burkle JW, et al. Atopic dermatitis independently increases sensitization above parental atopy: the MPAACH study. *J Allergy Clin Immunol.* 2020;145(5):1464–1466. doi:10.1016/j.jaci.2020.01.041

18. Sasaki T, Furusyo N, Shiohama A, et al. Filaggrin loss-of-function mutations are not a predisposing factor for atopic dermatitis in an Ishigaki Island under subtropical climate. *J Dermatol Sci.* 2014;76(1):10–15. doi:10.1016/j.jdermsci.2014.06.004
19. Nakatsuji T, Hata TR, Tong Y, et al. Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a Phase 1 randomized clinical trial. *Nat Med.* 2021;27(4):700–709. doi:10.1038/s41591-021-01256-2
20. Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. *Clin Rev Allergy Immunol.* 2016;51(3):329–337. doi:10.1007/s12016-016-8548-5
21. Grice K, Sattar H, Baker H, Sharratt M. The relationship of transepidermal water loss to skin temperature in psoriasis and eczema. *J Invest Dermatol.* 1975;64(5):313–315. doi:10.1111/1523-1747.ep12512258
22. Hon KL, Lam PH, Ng WG, et al. Age, sex, and disease status as determinants of skin hydration and transepidermal water loss among children with and without eczema. *Hong Kong Med J.* 2020;26(1):19–26. doi:10.12809/hkmj198150
23. Horimukai K, Morita K, Narita M, et al. Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations. *Allergol Int.* 2016;65(1):103–108. doi:10.1016/j.alit.2015.09.004
24. Sandilands A, Sutherland C, Irvine AD, McLean WH. Filaggrin in the frontline: role in skin barrier function and disease. *J Cell Sci.* 2009;122(Pt 9):1285–1294. doi:10.1242/jcs.033969
25. Abhishek S, Palamadai Krishnan S. Epidermal differentiation complex: a review on its epigenetic regulation and potential drug targets. *Cell J.* 2016;18(1):1–6. doi:10.22074/cellj.2016.3980
26. Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of Atopic Dermatitis with Filaggrin loss-of-function variant status. *Sci Rep.* 2020;10(1):2721. doi:10.1038/s41598-020-59627-7
27. Flohr C, England K, Radulovic S, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. *Br J Dermatol.* 2010;163(6):1333–1336. doi:10.1111/j.1365-2133.2010.10068.x
28. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet.* 2007;39(5):650–654. doi:10.1038/ng2020
29. Cai SC, Chen H, Koh WP, et al. Filaggrin mutations are associated with recurrent skin infection in Singaporean Chinese patients with atopic dermatitis. *Br J Dermatol.* 2012;166(1):200–203. doi:10.1111/j.1365-2133.2011.10541.x
30. Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by *Staphylococcus aureus*. *J Allergy Clin Immunol.* 2010;126(6):1184–1190 e1183. doi:10.1016/j.jaci.2010.09.015
31. Brown SJ, McLean WH. One remarkable molecule: filaggrin. *J Invest Dermatol.* 2012;132(3 Pt 2):751–762. doi:10.1038/jid.2011.393
32. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. *N Engl J Med.* 2011;365(14):1315–1327. doi:10.1056/NEJMra1011040
33. Omori-Miyake M, Yamashita M, Tsunemi Y, Kawashima M, Yagi J. In vitro assessment of IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice and humans. *J Invest Dermatol.* 2014;134(5):1342–1350. doi:10.1038/jid.2013.503
34. Cornelissen C, Marquardt Y, Czaja K, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. *J Allergy Clin Immunol.* 2012;129(2):426–433, 433 e421–428. doi:10.1016/j.jaci.2011.10.042
35. Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. *Int J Mol Sci.* 2020;21(8):115.
36. Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. *J Allergy Clin Immunol.* 2013;131(4):1094–1102. doi:10.1016/j.jaci.2012.12.1566
37. Marenholz I, Rivera VA, Esparza-Gordillo J, et al. Association screening in the Epidermal Differentiation Complex (EDC) identifies an SPRR3 repeat number variant as a risk factor for eczema. *J Invest Dermatol.* 2011;131(8):1644–1649. doi:10.1038/jid.2011.90
38. De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. *J Allergy Clin Immunol.* 2011;127(3):773–786 e771–777. doi:10.1016/j.jaci.2010.10.018
39. Asad S, Winge MC, Wahlgren CF, et al. The tight junction gene Claudin-1 is associated with atopic dermatitis among Ethiopians. *J Eur Acad Dermatol Venereol.* 2016;30(11):1939–1941. doi:10.1111/jdv.13806
40. Saunders SP, Goh CS, Brown SJ, et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. *J Allergy Clin Immunol.* 2013;132(5):1121–1129. doi:10.1016/j.jaci.2013.08.046
41. Sasaki T, Shiohama A, Kubo A, et al. A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis. *J Allergy Clin Immunol.* 2013;132(5):1111–1120 e1114. doi:10.1016/j.jaci.2013.08.027
42. Saunders SP, Floudas A, Moran T, et al. Dysregulated skin barrier function in Tmem79 mutant mice promotes IL-17A-dependent spontaneous skin and lung inflammation. *Allergy.* 2020;75(12):3216–3227. doi:10.1111/all.14488
43. Rasool R, Shafi T, Bhat IA, et al. Association of epidermal differentiation complex (EDC) genetic variants with House Dust Mite sensitization in Atopic Dermatitis Patients. *Immunobiology.* 2022;227(3):152214. doi:10.1016/j.imbio.2022.152214
44. Sliz E, Huilaja L, Pasanen A, et al. Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis. *J Allergy Clin Immunol.* 2022;149(3):1105–1112 e1109. doi:10.1016/j.jaci.2021.07.043
45. Romanowska M, Al Yacoub N, Seidel H, et al. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. *J Invest Dermatol.* 2008;128(1):110–124. doi:10.1038/sj.jid.5700943
46. Stevens ML, Zhang Z, Johansson E, et al. Disease-associated KIF3A variants alter gene methylation and expression impacting skin barrier and atopic dermatitis risk. *Nat Commun.* 2020;11(1):4092. doi:10.1038/s41467-020-17895-x
47. Blunder S, Pavel P, Minzaghi D, Dubrac S. PPARdelta in affected atopic dermatitis and psoriasis: a possible role in metabolic reprogramming. *Int J Mol Sci.* 2021;22(14):7354. doi:10.3390/ijms22147354
48. Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J. Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. *PLoS One.* 2010;5(3):e9701. doi:10.1371/journal.pone.0009701
49. Morgan E, Kannan-Thulasiraman P, Noy N. Involvement of fatty acid binding protein 5 and PPAR  $\beta/\delta$  in prostate cancer cell growth. *PPAR Res.* 2010;2010:1–9. doi:10.1155/2010/234629
50. Lee J, Kim B, Chu H, et al. FABP5 as a possible biomarker in atopic march: FABP5-induced Th17 polarization, both in mouse model and human samples. *EBioMedicine.* 2020;58:102879. doi:10.1016/j.ebiom.2020.102879



51. Elias MS, Wright SC, Remenyi J, et al. EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis. *J Allergy Clin Immunol.* 2019;144(2):470–481. doi:10.1016/j.jaci.2019.05.024
52. de Koning HD, Kamsteeg M, Rodijk-Olthuis D, et al. Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. *J Invest Dermatol.* 2011;131(1):263–266. doi:10.1038/jid.2010.278
53. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. *J Allergy Clin Immunol.* 2004;113(3):565–567. doi:10.1016/j.jaci.2003.12.583
54. Oh DY, Schumann RR, Hamann L, Neumann K, Worm M, Heine G. Association of the toll-like receptor 2 A-16934T promoter polymorphism with severe atopic dermatitis. *Allergy.* 2009;64(11):1608–1615. doi:10.1111/j.1398-9995.2009.02066.x
55. Niebuhr M, Heratizadeh A, Wichmann K, Satzger I, Werfel T. Intrinsic alterations of pro-inflammatory mediators in unstimulated and TLR-2 stimulated keratinocytes from atopic dermatitis patients. *Exp Dermatol.* 2011;20(6):468–472. doi:10.1111/j.1600-0625.2011.01277.x
56. Salpietro C, Rigoli L, Del Giudice MM, Miraglia Del Giudice M, et al. TLR2 and TLR4 gene polymorphisms and atopic dermatitis in Italian children: a multicenter study. *Int J Immunopathol Pharmacol.* 2011;24(4 Suppl):33–40. doi:10.1177/03946320110240S408
57. Can C, Yazicioglu M, Gurkan H, Tozkir H, Gorgulu A, Sut NH. Lack of association between toll-like receptor 2 polymorphisms (R753Q and A-16934T) and atopic dermatitis in children from Thrace region of Turkey. *Balkan Med J.* 2017;34(3):232–238. doi:10.4274/balkanmedj.2015.1253
58. Kaesler S, Volz T, Skabytska Y, et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. *J Allergy Clin Immunol.* 2014;134(1):92–99. doi:10.1016/j.jaci.2014.02.017
59. Novak N, Yu CF, Bussmann C, et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. *Allergy.* 2007;62(7):766–772. doi:10.1111/j.1398-9995.2007.01358.x
60. Levchenko LY, Izmailova OV, Shlykova OA et al. TLR4 896A/G gene polymorphism, rather than the TLR4 1196C/T and TLR2 2258G/Agene polymorphisms, determines severe and aggravated course of atopic dermatitis in children. *Cytol. Genet.* 2013;47(3):167–173. doi:10.3103/S0095452713030067
61. Kestra-Gounder AM, Tsoilis RM. NOD1 and NOD2: beyond peptidoglycan sensing. *Trends Immunol.* 2017;38(10):758–767. doi:10.1016/j.it.2017.07.004
62. Weidinger S, Klopp N, Rummeler L, et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. *J Allergy Clin Immunol.* 2005;116(1):177–184. doi:10.1016/j.jaci.2005.02.034
63. Negroni A, Pierdomenico M, Cucchiara S, Stronati L. NOD2 and inflammation: current insights. *J Inflamm Res.* 2018;11:49–60. doi:10.2147/JIR.S137606
64. Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: beyond filaggrin. *An Bras Dermatol.* 2016;91(4):472–478. doi:10.1590/abd1806-4841.20164412
65. Chieosilapatham P, Ogawa H, Niyonsaba F. Current insights into the role of human beta-defensins in atopic dermatitis. *Clin Exp Immunol.* 2017;190(2):155–166. doi:10.1111/cei.13013
66. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med.* 2002;347(15):1151–1160. doi:10.1056/NEJMoa021481
67. Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J Immunol.* 2003;171(6):3262–3269. doi:10.4049/jimmunol.171.6.3262
68. Hata TR, Kotol P, Boguniewicz M, et al. History of eczema herpeticum is associated with the inability to induce human beta-defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. *Br J Dermatol.* 2010;163(3):659–661. doi:10.1111/j.1365-2133.2010.09892.x
69. Kim E, Lee JE, Namkung JH, et al. Single nucleotide polymorphisms and the haplotype in the DEFB1 gene are associated with atopic dermatitis in a Korean population. *J Dermatol Sci.* 2009;54(1):25–30. doi:10.1016/j.jdermsci.2008.12.005
70. Segat L, Guimaraes RL, Brandao LA, et al. Beta defensin-1 gene (DEFB1) polymorphisms are not associated with atopic dermatitis in children and adolescents from northeast Brazil (Recife, Pernambuco). *Int J Dermatol.* 2010;49(6):653–657. doi:10.1111/j.1365-4632.2009.04343.x
71. Leung DY. Why is eczema herpeticum unexpectedly rare? *Antiviral Res.* 2013;98(2):153–157. doi:10.1016/j.antiviral.2013.02.010
72. Bin L, Edwards MG, Heiser R, et al. Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum. *J Allergy Clin Immunol.* 2014;134(4):848–855. doi:10.1016/j.jaci.2014.07.018
73. Gao PS, Leung DY, Rafaels NM, et al. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. *J Invest Dermatol.* 2012;132(3 Pt 1):650–657. doi:10.1038/jid.2011.374
74. Bin L, Malley C, Taylor P, et al. Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum. *Allergy.* 2021;76(8):2510–2523. doi:10.1111/all.14762
75. Kokubo K, Onodera A, Kiuchi M, Tsuji K, Hirahara K, Nakayama T. Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis. *Front Immunol.* 2022;13:945063. doi:10.3389/fimmu.2022.945063
76. Vaseghi-Shanjani M, Smith KL, Sara RJ, et al. Inborn errors of immunity manifesting as atopic disorders. *J Allergy Clin Immunol.* 2021;148(5):1130–1139. doi:10.1016/j.jaci.2021.08.008
77. Vaseghi-Shanjani M, Snow AL, Margolis DJ, et al. Atopy as immune dysregulation: offender genes and targets. *J Allergy Clin Immunol Pract.* 2022;10(7):1737–1756. doi:10.1016/j.jaip.2022.04.001
78. Albanesi C, Fairchild HR, Madonna S, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. *J Immunol.* 2007;179(2):984–992. doi:10.4049/jimmunol.179.2.984
79. Shang H, Cao XL, Wan YJ, Meng J, Guo LH. IL-4 gene polymorphism may contribute to an increased risk of atopic dermatitis in children. *Dis Markers.* 2016;2016:1021942. doi:10.1155/2016/1021942
80. He JQ, Chan-Yeung M, Becker AB, et al. Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children. *Genes Immun.* 2003;4(5):385–389. doi:10.1038/sj.gene.6363985
81. Sokolowska-Wojdylo M, Glen J, Zablorna M, et al. The frequencies of haplotypes defined by three polymorphisms of the IL-31 gene: -1066, -2057, and IVS2+12 in Polish patients with atopic dermatitis. *Int J Dermatol.* 2015;54(1):62–67. doi:10.1111/ijd.12666



82. Lan CC, Tu HP, Wu CS, et al. Distinct SPINK5 and IL-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population. *Exp Dermatol*. 2011;20(12):975–979. doi:10.1111/j.1600-0625.2011.01374.x
83. Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. *Expert Rev Clin Immunol*. 2021;17(8):835–852. doi:10.1080/1744666X.2021.1940962
84. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat Immunol*. 2002;3(7):673–680. doi:10.1038/ni805
85. Nakajima S, Igyarto BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. *J Allergy Clin Immunol*. 2012;129(4):1048–1055 e1046. doi:10.1016/j.jaci.2012.01.063
86. Bell BD, Kitajima M, Larson RP, et al. The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. *Nat Immunol*. 2013;14(4):364–371. doi:10.1038/ni.2541
87. Rochman Y, Kashyap M, Robinson GW, et al. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. *Proc Natl Acad Sci U S A*. 2010;107(45):19455–19460. doi:10.1073/pnas.1008271107
88. Margolis DJ, Kim B, Apter AJ, et al. Thymic stromal lymphopoietin variation, flaggrin loss of function, and the persistence of atopic dermatitis. *JAMA Dermatol*. 2014;150(3):254–259. doi:10.1001/jamadermatol.2013.7954
89. Berna R, Mitra N, Lou C, et al. TSLP and IL-7R variants are associated with persistent atopic dermatitis. *J Invest Dermatol*. 2021;141(2):446–450 e442. doi:10.1016/j.jid.2020.05.119
90. Gao PS, Rafaels NM, Mu D, et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. *J Allergy Clin Immunol*. 2010;125(6):1403–1407 e1404. doi:10.1016/j.jaci.2010.03.016
91. Walford HH, Doherty TA. STAT6 and lung inflammation. *JAKSTAT*. 2013;2(4):e25301. doi:10.4161/jkst.25301
92. Makita S, Takatori H, Matsuki A, et al. T-bet and STAT6 coordinately suppress the development of IL-9-mediated atopic dermatitis-like skin inflammation in mice. *J Invest Dermatol*. 2021;141(5):1274–1285 e1275. doi:10.1016/j.jid.2020.08.029
93. Howell M D et al. (2011). The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. *J Allergy Clin Immunol*, 128(5), 1006–14. doi:10.1016/j.jaci.2011.06.003
94. Folster-Holst R, Moises HW, Yang L, Fritsch W, Weissenbach J, Christophers E. Linkage between atopy and the IgE high-affinity receptor gene at 11q13 in atopic dermatitis families. *Hum Genet*. 1998;102(2):236–239. doi:10.1007/s004390050685
95. Cookson WO, Sharp PA, Faux JA, Hopkin JM. Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome 11q. *Lancet*. 1989;1(8650):1292–1295. doi:10.1016/S0140-6736(89)92687-1
96. Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. *Am J Hum Genet*. 2012;90(5):796–808. doi:10.1016/j.ajhg.2012.03.013
97. Israel L, Mellett M. Clinical and genetic heterogeneity of CARD14 mutations in psoriatic skin disease. *Front Immunol*. 2018;9:2239. doi:10.3389/fimmu.2018.02239
98. Heo WI, Park KY, Lee MK, Bae YJ, Moon NJ, Seo SJ. Association of DOCK8, IL17RA, and KLK12 polymorphisms with atopic dermatitis in Koreans. *Ann Dermatol*. 2020;32(3):197–205. doi:10.5021/ad.2020.32.3.197
99. Nousbeck J, Irvine AD. Atopic dermatitis according to GARP: new mechanistic insights in disease pathogenesis. *J Invest Dermatol*. 2016;136(12):2340–2341. doi:10.1016/j.jid.2016.08.020
100. Fridrich S, Hahn SA, Linzmaier M, et al. How soluble GARP enhances TGFbeta activation. *PLoS One*. 2016;11(4):e0153290. doi:10.1371/journal.pone.0153290
101. Chen XY, Zhu XJ, Chen M, et al. GARP polymorphisms associated with susceptibility to house dust mite-sensitized persistent allergic rhinitis in a Chinese population. *J Asthma Allergy*. 2022;15:1369–1381. doi:10.2147/JAA.S366815
102. Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. *World Allergy Organ J*. 2021;14(3):100519. doi:10.1016/j.waojou.2021.100519
103. Arthur GK, Cruse G. Regulation of trafficking and signaling of the high affinity IgE receptor by FcepsilonRIbeta and the potential impact of FcepsilonRIbeta splicing in allergic inflammation. *Int J Mol Sci*. 2022;23(2):788. doi:10.3390/ijms23020788
104. Zeller S, Rhyner C, Meyer N, Schmid-Grendelmeier P, Akdis CA, Cramer R. Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. *J Allergy Clin Immunol*. 2009;124(2):278–285, 285 e271–277. doi:10.1016/j.jaci.2009.05.015
105. Vuckovic D, Bao EL, Akbari P, et al. The polygenic and monogenic basis of blood traits and diseases. *Cell*. 2020;182(5):1214–1231 e1211. doi:10.1016/j.cell.2020.08.008
106. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. *Allergy*. 2004;59(6):561–570. doi:10.1111/j.1398-9995.2004.00476.x
107. Arriba-Mendez S, Sanz C, Isidoro-Garcia M, et al. 927T>C polymorphism of the cysteinyl-leukotriene type-1 receptor (CYSLTR1) gene in children with asthma and atopic dermatitis. *Pediatr Allergy Immunol*. 2006;17(5):323–328. doi:10.1111/j.1399-3038.2006.00416.x
108. Acevedo N, Benfeitas R, Katayama S, et al. Epigenetic alterations in skin homing CD4(+)/CLA(+) T cells of atopic dermatitis patients. *Sci Rep*. 2020;10(1):18020. doi:10.1038/s41598-020-74798-z
109. Kim HO, Kim JH, Chung BY, Choi MG, Park CW. Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases. *Exp Dermatol*. 2014;23(4):278–281. doi:10.1111/exd.12350
110. Suzuki T, Hidaka T, Kumagai Y, Yamamoto M. Environmental pollutants and the immune response. *Nat Immunol*. 2020;21(12):1486–1495. doi:10.1038/s41590-020-0802-6
111. Hidaka T, Ogawa E, Kobayashi EH, et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. *Nat Immunol*. 2017;18(1):64–73. doi:10.1038/ni.3614
112. Tauchi M, Hida A, Negishi T, et al. Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions. *Mol Cell Biol*. 2005;25(21):9360–9368. doi:10.1128/MCB.25.21.9360-9368.2005
113. Schmidt AD, de Guzman Strong C. Current understanding of epigenetics in atopic dermatitis. *Exp Dermatol*. 2021;30(8):1150–1155. doi:10.1111/exd.14392
114. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res*. 2012;22(5):850–859. doi:10.1101/gr.131029.111

115. Traisaeng S, Herr DR, Kao HJ, Chuang TH, Huang CM. A derivative of butyric acid, the fermentation metabolite of *Staphylococcus epidermidis*, inhibits the growth of a *Staphylococcus aureus* strain isolated from atopic dermatitis patients. *Toxins*. 2019;11(6):311. doi:10.3390/toxins11060311
116. Hsu AP, Davis J, Puck JM, et al. STAT3 hyper IgE syndrome. In: Adam MP, Everman DB, Mirzaa GM, editors. *GeneReviews*(R). Seattle (WA): MedlinePlus; 1993.
117. Nelson RW, Geha RS, McDonald DR. Inborn errors of the immune system associated with atopy. *Front Immunol*. 2022;13:860821. doi:10.3389/fimmu.2022.860821
118. Villa A, Santagata S, Bozzi F, Imberti L, Notarangelo LD. Omenn syndrome: a disorder of Rag1 and Rag2 genes. *J Clin Immunol*. 1999;19(2):87–97. doi:10.1023/A:1020550432126
119. Malik MA, Masab M. *Wiskott-Aldrich Syndrome*. Treasure Island (FL): StatPearls; 2022.
120. Hershfield M. Adenosine deaminase deficiency. In: Adam MP, Everman DB, Mirzaa GM, editors. *GeneReviews*(R). Seattle (WA): MedlinePlus; 1993.
121. Tan QKG, Louie RJ, Sleasman JW, et al. IPEX syndrome. In: Adam MP, Everman DB, Mirzaa GM, editors. *GeneReviews*(R). Seattle (WA): MedlinePlus; 1993.
122. Stray-Pedersen A, Backe PH, Sorte HS, et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. *Am J Hum Genet*. 2014;95(1):96–107. doi:10.1016/j.ajhg.2014.05.007
123. Zhang Y, Yu X, Ichikawa M, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. *J Allergy Clin Immunol*. 2014;133(5):1400–1409, 1409 e1401–1405. doi:10.1016/j.jaci.2014.02.013
124. Alrumayyan N, Slauenwhite D, McAlpine SM, et al. Prolidase deficiency, a rare inborn error of immunity, clinical phenotypes, immunological features, and proposed treatments in twins. *Allergy Asthma Clin Immunol*. 2022;18(1):17. doi:10.1186/s13223-022-00658-2
125. Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. *Nat Genet*. 2013;45(10):1244–1248. doi:10.1038/ng.2739
126. Liang J, Li C, Zhang Z, et al. Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of Acitretin with gabapentin. *J Dermatol*. 2019;46(7):622–625. doi:10.1111/1346-8138.14925
127. Raghunath M, Tontsidou L, Oji V, et al. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. *J Invest Dermatol*. 2004;123(3):474–483. doi:10.1111/j.0022-202X.2004.23220.x
128. Klammt J, Neumann D, Gevers EF, et al. Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation. *Nat Commun*. 2018;9(1):2105. doi:10.1038/s41467-018-04521-0
129. Pugliese-Pires PN, Tonelli CA, Dora JM, et al. A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings. *Eur J Endocrinol*. 2010;163(2):349–355. doi:10.1530/EJE-10-0272
130. Sharma M, Lu HY, Vaseghi-Shanjani M, et al. Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. *medRxiv*. 2022;2022.22274265.
131. Gaudinski MR, Milner JD. Atopic dermatitis and allergic urticaria: cutaneous manifestations of immunodeficiency. *Immunol Allergy Clin North Am*. 2017;37(1):1–10. doi:10.1016/j.iac.2016.08.016
132. Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. *JAKSTAT*. 2013;2(3):e24137. doi:10.4161/jkst.24137
133. Hashimoto T, Sakai K, Yosipovitch G, Akiyama T. Signal transducer and activator of transcription 3 in keratinocytes regulates histaminergic itch but not nonhistaminergic itch. *Acta Derm Venereol*. 2019;99(10):901–902. doi:10.2340/00015555-3229
134. Baik M, Yu JH, Hennighausen L. Growth hormone-STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism. *Ann N Y Acad Sci*. 2011;1229:29–37. doi:10.1111/j.1749-6632.2011.06100.x
135. Kim CH. FOXP3 and its role in the immune system. *Adv Exp Med Biol*. 2009;665:17–29.
136. Bosa L, Batura V, Colavito D, et al. Novel CARMIL2 loss-of-function variants are associated with pediatric inflammatory bowel disease. *Sci Rep*. 2021;11(1):5945. doi:10.1038/s41598-021-85399-9
137. Cristalli G, Costanzi S, Lambertucci C, et al. Adenosine deaminase: functional implications and different classes of inhibitors. *Med Res Rev*. 2001;21(2):105–128. doi:10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U
138. Lawrence MG, Barber JS, Sokolic RA, et al. Elevated IgE and atopy in patients treated for early-onset ADA-SCID. *J Allergy Clin Immunol*. 2013;132(6):1444–1446. doi:10.1016/j.jaci.2013.05.040
139. Helmink BA, Sleckman BP. The response to and repair of RAG-mediated DNA double-strand breaks. *Annu Rev Immunol*. 2012;30:175–202. doi:10.1146/annurev-immunol-030409-101320
140. Kearney CJ, Randall KL, Oliaro J. DOCK8 regulates signal transduction events to control immunity. *Cell Mol Immunol*. 2017;14(5):406–411. doi:10.1038/cmi.2017.9
141. Kulkarni K, Yang J, Zhang Z, Barford D. Multiple factors confer specific Cdc42 and Rac protein activation by dedicator of cytokinesis (DOCK) nucleotide exchange factors. *J Biol Chem*. 2011;286(28):25341–25351. doi:10.1074/jbc.M111.236455
142. Tangye SG, Pillay B, Randall KL, et al. Dedicator of cytokinesis 8-deficient CD4(+) T cells are biased to a TH2 effector fate at the expense of TH1 and TH17 cells. *J Allergy Clin Immunol*. 2017;139(3):933–949. doi:10.1016/j.jaci.2016.07.016
143. Sun X, Wei Y, Lee PP, Ren B, Liu C. The role of WASp in T cells and B cells. *Cell Immunol*. 2019;341:103919. doi:10.1016/j.cellimm.2019.04.007
144. Sassi A, Lazaroski S, Wu G, et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. *J Allergy Clin Immunol*. 2014;133(5):1410–1419, 1419 e1411–1413. doi:10.1016/j.jaci.2014.02.025
145. Deraison C, Bonnart C, Lopez F, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. *Mol Biol Cell*. 2007;18(9):3607–3619. doi:10.1091/mbc.e07-02-0124
146. Walley AJ, Chavanas S, Moffatt MF, et al. Gene polymorphism in Netherton and common atopic disease. *Nat Genet*. 2001;29(2):175–178. doi:10.1038/ng728

147. Polivka L, Hadj-Rabia S, Bal E, et al. Epithelial barrier dysfunction in desmoglein-1 deficiency. *J Allergy Clin Immunol.* 2018;142(2):702–706 e707. doi:10.1016/j.jaci.2018.04.007
148. Arehart CH, Daya M, Campbell M, et al. Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors. *J Allergy Clin Immunol.* 2022;149(1):145–155. doi:10.1016/j.jaci.2021.05.034
149. Wray NR, Kemper KE, Hayes BJ, Goddard ME, Visscher PM. Complex trait prediction from genome data: contrasting EBV in livestock to PRS in humans: genomic prediction. *Genetics.* 2019;211(4):1131–1141. doi:10.1534/genetics.119.301859
150. Brown SJ. Atopic eczema: how genetic studies can contribute to the understanding of this complex trait. *J Invest Dermatol.* 2022;142(4):1015–1019. doi:10.1016/j.jid.2021.12.020
151. Chen Y, Chen W. Genome-wide integration of genetic and genomic studies of atopic dermatitis: insights into genetic architecture and pathogenesis. *J Invest Dermatol.* 2022. doi:10.1016/j.jid.2022.04.021
152. Baurecht H, Hotze M, Brand S, et al. Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. *Am J Hum Genet.* 2015;96(1):104–120. doi:10.1016/j.ajhg.2014.12.004
153. Budu-Aggrey A, Watkins SH, Brumpton B, et al. Assessment of a causal relationship between body mass index and atopic dermatitis. *J Allergy Clin Immunol.* 2021;147(1):400–403. doi:10.1016/j.jaci.2020.04.050
154. Brown SJ. What have we learned from GWAS for atopic dermatitis? *J Invest Dermatol.* 2021;141(1):19–22. doi:10.1016/j.jid.2020.05.100
155. Blakeway H, Van-de-velde V, Allen VB, et al. What is the evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of atopic dermatitis? A systematic review. *Br J Dermatol.* 2020;183(3):443–451. doi:10.1111/bjd.18778
156. Totte JE, van der Feltz WT, Hennekam M, van Belkum A, Van Zuuren EJ, Pasmans SG. Prevalence and odds of *Staphylococcus aureus* carriage in atopic dermatitis: a systematic review and meta-analysis. *Br J Dermatol.* 2016;175(4):687–695. doi:10.1111/bjd.14566
157. Tauber M, Balica S, Hsu CY, et al. *Staphylococcus aureus* density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. *J Allergy Clin Immunol.* 2016;137(4):1272–1274 e1273. doi:10.1016/j.jaci.2015.07.052
158. Blicharz L, Michalak M, Szymanek-Majchrzak K, et al. The propensity to form biofilm in vitro by *Staphylococcus aureus* strains isolated from the anterior nares of patients with atopic dermatitis: clinical associations. *Dermatology.* 2021;237(4):528–534. doi:10.1159/000511182
159. Blicharz L, Usarek P, Mlynarczyk G, Skowronski K, Rudnicka L, Samochocki Z. Is itch intensity in atopic dermatitis associated with skin colonization by *Staphylococcus aureus*? *Indian J Dermatol.* 2020;65(1):17–21. doi:10.4103/ijid.IJD\_136\_19
160. Allen HB, Vaze ND, Choi C, et al. The presence and impact of biofilm-producing staphylococci in atopic dermatitis. *JAMA Dermatol.* 2014;150(3):260–265. doi:10.1001/jamadermatol.2013.8627
161. Di Domenico EG, Cavallo I, Bordignon V, et al. Inflammatory cytokines and biofilm production sustain *Staphylococcus aureus* outgrowth and persistence: a pivotal interplay in the pathogenesis of Atopic Dermatitis. *Sci Rep.* 2018;8(1):9573. doi:10.1038/s41598-018-27421-1
162. Kim JE, Kim HS. Microbiome of the skin and gut in Atopic Dermatitis (AD): understanding the pathophysiology and finding novel management strategies. *J Clin Med.* 2019;8(4):120.
163. Abad ED, Ferreira DC, Cavalcante FS, et al. High incidence of acquiring methicillin-resistant *Staphylococcus aureus* in Brazilian children with Atopic Dermatitis and associated risk factors. *J Microbiol Immunol Infect.* 2020;53(5):724–730. doi:10.1016/j.jmii.2018.12.014
164. Chung HJ, Jeon HS, Sung H, Kim MN, Hong SJ. Epidemiological characteristics of methicillin-resistant *Staphylococcus aureus* isolates from children with eczematous atopic dermatitis lesions. *J Clin Microbiol.* 2008;46(3):991–995. doi:10.1128/JCM.00698-07
165. Jagadeesan S, Kurien G, Divakaran MV, Sadanandan SM, Sobhanakumari K, Sarin A. Methicillin-resistant *Staphylococcus aureus* colonization and disease severity in atopic dermatitis: a cross-sectional study from South India. *Indian J Dermatol Venereol Leprol.* 2014;80(3):229–234. doi:10.4103/0378-6323.132250
166. Lo WT, Wang SR, Tseng MH, Huang CF, Chen SJ, Wang CC. Comparative molecular analysis of methicillin-resistant *Staphylococcus aureus* isolates from children with atopic dermatitis and healthy subjects in Taiwan. *Br J Dermatol.* 2010;162(5):1110–1116. doi:10.1111/j.1365-2133.2010.09679.x
167. Leung DY, Hanifin JM, Piserer DM, et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. *Br J Dermatol.* 2009;161(2):435–443. doi:10.1111/j.1365-2133.2009.09145.x
168. Seiti Yamada Yoshikawa F, Feitosa de Lima J, Notomi Sato M, Alefe Leuzzi Ramos Y, Aoki V, Leao Orfali R. Exploring the role of *Staphylococcus aureus* toxins in atopic dermatitis. *Toxins.* 2019;11(6):321. doi:10.3390/toxins11060321
169. van Drongelen V, Haisma EM, Out-Luiting JJ, Nibbering PH, El Ghalbzouri A. Reduced filaggrin expression is accompanied by increased *Staphylococcus aureus* colonization of epidermal skin models. *Clin Exp Allergy.* 2014;44(12):1515–1524. doi:10.1111/cea.12443
170. Schlievert PM, Strandberg KL, Lin YC, Peterson ML, Leung DY. Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive *Staphylococcus aureus*, and its relevance to atopic dermatitis. *J Allergy Clin Immunol.* 2010;125(1):39–49. doi:10.1016/j.jaci.2009.10.039
171. Leung D. Superantigens, steroid insensitivity and innate immunity in atopic eczema. *Acta Derm Venereol Suppl.* 2005;(215):11–15. doi:10.1080/03658340510012435
172. Breuer K, Wittmann M, Kempe K, et al. Alpha-toxin is produced by skin colonizing *Staphylococcus aureus* and induces a T helper type 1 response in atopic dermatitis. *Clin Exp Allergy.* 2005;35(8):1088–1095. doi:10.1111/j.1365-2222.2005.02295.x
173. Ezechuk YV, Leung DY, Middleton MH, Bina P, Reiser R, Norris DA. Staphylococcal toxins and protein A differentially induce cytotoxicity and release of tumor necrosis factor-alpha from human keratinocytes. *J Invest Dermatol.* 1996;107(4):603–609. doi:10.1111/1523-1747.ep12583377
174. Brauweiler AM, Goleva E, Leung DYM. Th2 cytokines increase *Staphylococcus aureus* alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). *J Invest Dermatol.* 2014;134(8):2114–2121. doi:10.1038/jid.2014.43
175. Brauweiler AM, Bin L, Kim BE, et al. Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal alpha-toxin-induced keratinocyte death. *J Allergy Clin Immunol.* 2013;131(2):421–427 e421–422. doi:10.1016/j.jaci.2012.10.030
176. Baldry M, Nakamura Y, Nakagawa S, et al. Application of an agr-specific antivirulence compound as therapy for *Staphylococcus aureus*-induced inflammatory skin disease. *J Infect Dis.* 2018;218(6):1009–1013. doi:10.1093/infdis/jiy259
177. Azimi E, Reddy VB, Lerner EA. Brief communication: MRGPRX2, atopic dermatitis and red man syndrome. *Itch.* 2017;2(1):e5–e5. doi:10.1097/itx.000000000000005

178. Cruz AR, Boer MAD, Strasser J, et al. Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer formation. *Proc Natl Acad Sci U S A*. 2021;118(7). doi:10.1073/pnas.2016772118
179. Zipperer A, Konnerth MC, Laux C, et al. Human commensals producing a novel antibiotic impair pathogen colonization. *Nature*. 2016;535(7613):511–516. doi:10.1038/nature18634
180. Nakatsuji T, Gallo RL. The role of the skin microbiome in atopic dermatitis. *Ann Allergy Asthma Immunol*. 2019;122(3):263–269. doi:10.1016/j.anai.2018.12.003
181. Lai Y, Cogen AL, Radek KA, et al. Activation of TLR2 by a small molecule produced by *Staphylococcus epidermidis* increases antimicrobial defense against bacterial skin infections. *J Invest Dermatol*. 2010;130(9):2211–2221. doi:10.1038/jid.2010.123
182. Myles IA, Earland NJ, Anderson ED, et al. First-in-human topical microbiome transplantation with *Roseomonas mucosa* for atopic dermatitis. *JCI Insight*. 2018;3(9). doi:10.1172/jci.insight.120608
183. Myles IA, Williams KW, Reckhow JD, et al. Transplantation of human skin microbiota in models of atopic dermatitis. *JCI Insight*. 2016;1(10). doi:10.1172/jci.insight.86955
184. Ramsey MM, Freire MO, Gabriliska RA, Rumbaugh KP, Lemon KP. *Staphylococcus aureus* shifts toward commensalism in response to corynebacterium species. *Front Microbiol*. 2016;7:1230. doi:10.3389/fmicb.2016.01230
185. Shu M, Wang Y, Yu J, et al. Fermentation of *Propionibacterium acnes*, a commensal bacterium in the human skin microbiome, as skin probiotics against methicillin-resistant *Staphylococcus aureus*. *PLoS One*. 2013;8(2):e55380. doi:10.1371/journal.pone.0055380
186. Parlet CP, Brown MM, Horswill AR. Commensal staphylococci influence *Staphylococcus aureus* skin colonization and disease. *Trends Microbiol*. 2019;27(6):497–507. doi:10.1016/j.tim.2019.01.008
187. Linehan JL, Harrison OJ, Han SJ, et al. Non-classical immunity controls microbiota impact on skin immunity and tissue repair. *Cell*. 2018;172(4):784–796 e718. doi:10.1016/j.cell.2017.12.033
188. Lai Y, Di Nardo A, Nakatsuji T, et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. *Nat Med*. 2009;15(12):1377–1382. doi:10.1038/nm.2062
189. Meijer K, de Vos P, Priebe M G. (2010). Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?. *Curr Opin Clin Nutr Metab Care*, 13(6), 715–21. doi:10.1097/MCO.0b013e32833eebe5
190. Wang Y, Keefer M, Ong PY. Antibiotic choice and methicillin-resistant *Staphylococcus aureus* rate in children hospitalized for atopic dermatitis. *Ann Allergy Asthma Immunol*. 2019;122(3):314–317. doi:10.1016/j.anai.2018.12.001
191. Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. *J Am Acad Dermatol*. 2003;49(2):198–205. doi:10.1067/S0190-9622(03)00896-X
192. Xiao A, Tsuchiya A. *Eczema Herpeticum*. Treasure Island (FL): StatPearls; 2022.
193. Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. *J Allergy Clin Immunol*. 2009;124(2):260–269. doi:10.1016/j.jaci.2009.05.020
194. Manti S, Amorini M, Cuppari C, et al. Filaggrin mutations and *Molluscum contagiosum* skin infection in patients with atopic dermatitis. *Ann Allergy Asthma Immunol*. 2017;119(5):446–451. doi:10.1016/j.anai.2017.07.019
195. Berger EM, Orlov SJ, Patel RR, Schaffer JV. Experience with molluscum contagiosum and associated inflammatory reactions in a pediatric dermatology practice: the bump that rashes. *Arch Dermatol*. 2012;148(11):1257–1264. doi:10.1001/archdermatol.2012.2414
196. Johnson VK, Hayman JL, McCarthy CA, Cardona ID. Successful treatment of eczema coxsackium with wet wrap therapy and low-dose topical corticosteroid. *J Allergy Clin Immunol Pract*. 2014;2(6):803–804. doi:10.1016/j.jaip.2014.07.018
197. Reed JL, Scott DE, Bray M. Eczema vaccinatum. *Clin Infect Dis*. 2012;54(6):832–840. doi:10.1093/cid/cir952
198. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. *PLoS Negl Trop Dis*. 2022;16(2):e0010141. doi:10.1371/journal.pntd.0010141
199. World Health Organization. Multi-country monkeypox outbreak in non-endemic countries: update; 2022. Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON388>. Accessed June 4, 2022.
200. Howell M D, Gallo R L, Boguniewicz M, Jones J F, Wong C, Streib J E, Leung D Y. (2006). Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. *Immunity*, 24(3), 341–8. doi:10.1016/j.immuni.2006.02.006
201. Oyoshi MK, Elkhali A, Kumar L, et al. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. *Proc Natl Acad Sci U S A*. 2009;106(35):14954–14959. doi:10.1073/pnas.0904021106
202. Oyoshi MK, Murphy GF, Geha RS. Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. *J Allergy Clin Immunol*. 2009;124(3):485–493. doi:10.1016/j.jaci.2009.05.042
203. Prevention CfDca. Smallpox vaccines. Available from: <https://www.cdc.gov/smallpox/clinicians/vaccines.html>. Accessed June 4, 2022.
204. Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The role of *Malassezia* spp. in atopic dermatitis. *J Clin Med*. 2015;4(6):1217–1228. doi:10.3390/jcm4061217
205. Kaga M, Sugita T, Nishikawa A, Wada Y, Hiruma M, Ikeda S. (2011). Molecular analysis of the cutaneous *Malassezia* microbiota from the skin of patients with atopic dermatitis of different severities. *Mycoses*, 54(4), e24–8. doi:10.1111/j.1439-0507.2009.01821.x
206. Sugita T, Suto H, Unno T, et al. Molecular analysis of *Malassezia* microflora on the skin of atopic dermatitis patients and health subjects. *J Clin Microbiol*. 2001;39(10):3486–3490. doi:10.1128/JCM.39.10.3486-3490.2001
207. Bjerre R D, Bandier J, Skov L, Engstrand L, Johansen J D. (2017). The role of the skin microbiome in atopic dermatitis: a systematic review. *Br J Dermatol*, 177(5), 1272–1278. doi:10.1111/bjd.15390
208. Broberg A, Faergemann J. Topical antimycotic treatment of atopic dermatitis in the head/neck area. A double-blind randomised study. *Acta Derm Venereol*. 1995;75(1):46–49. doi:10.2340/00015555754649
209. Werfel T, Heratizadeh A, Niebuhr M, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. *J Allergy Clin Immunol*. 2015;136(1):96–103 e109. doi:10.1016/j.jaci.2015.04.015
210. Chong AC, Chwa WJ, Ong PY. Aeroallergens in atopic dermatitis and chronic urticaria. *Curr Allergy Asthma Rep*. 2022;22:67–75. doi:10.1007/s11882-022-01033-2
211. Kutlu A, Karabacak E, Aydin E, et al. Relationship between skin prick and atopic patch test reactivity to aeroallergens and disease severity in children with atopic dermatitis. *Allergol Immunopathol*. 2013;41(6):369–373. doi:10.1016/j.aller.2013.02.007



212. Serhan N, Basso L, Sibilano R, et al. House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation. *Nat Immunol.* 2019;20(11):1435–1443. doi:10.1038/s41590-019-0493-z
213. Butuci M, Benet Z, Wong A, et al. Mast cells are locally activated and respond to MRGPRX2 stimulation in atopic dermatitis ex vivo skin biopsies. *J Allergy Clin Immunol.* 2022;149(2):AB5–AB5. doi:10.1016/j.jaci.2021.12.058
214. Lee Y, Lee E, Yon DK, et al. The potential pathways underlying the association of propyl-paraben exposure with aeroallergen sensitization and EASI score using metabolomics analysis. *Sci Rep.* 2021;11(1):3772. doi:10.1038/s41598-021-83288-9
215. Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. *Allergy.* 2018;73(10):2046–2054. doi:10.1111/all.13454
216. Anderson LB, Dreyfuss EM, Logan J, Johnstone DE, Glaser J. Melon and banana sensitivity coincident with ragweed pollinosis. *J Allergy.* 1970;45(5):310–319. doi:10.1016/0021-8707(70)90037-7
217. Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. *J Eur Acad Dermatol Venereol.* 2020;34(12):2717–2744. doi:10.1111/jdv.16892
218. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. *Allergy.* 2006;61(2):202–205. doi:10.1111/j.1398-9995.2006.00974.x
219. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. *J Allergy Clin Immunol.* 2007;120(1):164–170. doi:10.1016/j.jaci.2007.04.008
220. Langer SS, Cardili RN, Melo JML, et al. Efficacy of house dust mite sublingual immunotherapy in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol Pract.* 2022;10(2):539–549 e537. doi:10.1016/j.jaip.2021.10.060
221. Fadadu RP, Grimes B, Jewell NP, et al. Association of wildfire air pollution and health care use for atopic dermatitis and itch. *JAMA Dermatol.* 2021;157(6):658–666. doi:10.1001/jamadermatol.2021.0179
222. Park SK, Kim JS, Seo HM. Exposure to air pollution and incidence of atopic dermatitis in the general population: a national population-based retrospective cohort study. *J Am Acad Dermatol.* 2021. doi:10.1016/j.jaad.2021.05.061
223. Ye C, Gu H, Li M, Chen R, Xiao X, Zou Y. Air pollution and weather conditions are associated with daily outpatient visits of atopic dermatitis in Shanghai, China. *Dermatology.* 2022;1–11. doi:10.1159/000526143
224. Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. *J Am Acad Dermatol.* 2016;75(6):1119–1125 e1111. doi:10.1016/j.jaad.2016.07.017
225. Edamitsu T, Taguchi K, Okuyama R, Yamamoto M. AHR and NRF2 in skin homeostasis and atopic dermatitis. *Antioxidants.* 2022;11(2):227. doi:10.3390/antiox11020227
226. Kim BE, Kim J, Goleva E, et al. Particulate matter causes skin barrier dysfunction. *JCI Insight.* 2021;6(5). doi:10.1172/jci.insight.145185
227. Woo YR, Park SY, Choi K, Hong ES, Kim S, Kim HS. Air pollution and atopic dermatitis (AD): the impact of particulate matter (PM10) on an AD mouse-model. *Int J Mol Sci.* 2020;21(17):6079. doi:10.3390/ijms21176079
228. Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. *J Invest Dermatol.* 2013;133(7):1752–1759. doi:10.1038/jid.2013.19
229. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. *Expert Rev Clin Immunol.* 2017;13(1):15–26. doi:10.1080/1744666X.2016.1212660
230. Legat FJ. The antipruritic effect of phototherapy. *Front Med.* 2018;5:333. doi:10.3389/fmed.2018.00333
231. Bonnelykke K, Pippert CB, Tavendale R, Palmer CN, Bisgaard H. Filaggrin gene variants and atopic diseases in early childhood assessed longitudinally from birth. *Pediatr Allergy Immunol.* 2010;21(6):954–961. doi:10.1111/j.1399-3038.2010.01073.x
232. Schuttelaar ML, Kerkhof M, Jonkman MF, et al. Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure. *Allergy.* 2009;64(12):1758–1765. doi:10.1111/j.1398-9995.2009.02080.x
233. Cramer C, Link E, Horster M, et al. Elder siblings enhance the effect of filaggrin mutations on childhood eczema: results from the 2 birth cohort studies LISAPlus and GINIplus. *J Allergy Clin Immunol.* 2010;125(6):1254–1260 e1255. doi:10.1016/j.jaci.2010.03.036
234. Brown SJ, Relton CL, Liao H, et al. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. *Br J Dermatol.* 2009;161(4):884–889. doi:10.1111/j.1365-2133.2009.09339.x
235. Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. *J Allergy Clin Immunol.* 2008;121(4):872–877 e879. doi:10.1016/j.jaci.2008.01.026
236. Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. *J Invest Dermatol.* 2006;126(6):1200–1202. doi:10.1038/sj.jid.5700365
237. Rustad AM, Nickles MA, Bilimoria SN, Lio PA. The role of diet modification in atopic dermatitis: navigating the complexity. *Am J Clin Dermatol.* 2022;23(1):27–36. doi:10.1007/s40257-021-00647-y
238. Oykman P, Dookie J, Al-Rammahy H, et al. Dietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis. *J Allergy Clin Immunol Pract.* 2022;10(10):2657–2666 e2658. doi:10.1016/j.jaip.2022.06.044
239. Kim JH. Role of breast-feeding in the development of atopic dermatitis in early childhood. *Allergy Asthma Immunol Res.* 2017;9(4):285–287. doi:10.4168/aaar.2017.9.4.285
240. Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. *Hum Vaccin Immunother.* 2019;15(9):2129–2139. doi:10.1080/21645515.2019.1582403
241. Charvet E, Bourrat E, Hickman G, et al. Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant. *Clin Exp Dermatol.* 2021;46(7):1334–1335. doi:10.1111/ced.14686
242. Ollech A, Mashiah J, Lev A, et al. Treatment options for DOCK8 deficiency-related severe dermatitis. *J Dermatol.* 2021;48(9):1386–1393. doi:10.1111/1346-8138.15955
243. Joshi TP, Anvari S, Gupta MR, Davis CM, Hajjar J. Case report: dupilumab successfully controls severe eczema in a child with elevated IgE levels and recurrent skin infections. *Front Pediatr.* 2021;9:646997. doi:10.3389/fped.2021.646997

244. Droghini HR, Abonia JP, Collins MH, et al. Targeted IL-4Ralpha blockade ameliorates refractory allergic eosinophilic inflammation in a patient with dysregulated TGF-beta signaling due to ERBIN deficiency. *J Allergy Clin Immunol Pract.* 2022;10(7):1903–1906. doi:10.1016/j.jaip.2022.01.012
245. Steuer AB, Cohen DE. Treatment of Netherton syndrome with dupilumab. *JAMA Dermatol.* 2020;156(3):350–351. doi:10.1001/jamadermatol.2019.4608
246. Lu CW, Lee WI, Chung WH. Dupilumab for STAT3-hyper-IgE syndrome with refractory intestinal complication. *Pediatrics.* 2021;148(3). doi:10.1542/peds.2021-050351
247. Matucci-Cerinic C, Viglizzo G, Pastorino C, et al. Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome. *Pediatr Allergy Immunol.* 2022;33(4):e13770. doi:10.1111/pai.13770
248. Sogkas G, Hirsch S, Jablonka A, Witte T, Schmidt RE, Atschekzei F. Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome. *Clin Immunol.* 2020;215:108452. doi:10.1016/j.clim.2020.108452
249. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. *J Allergy Clin Immunol.* 2021;148(4):927–940. doi:10.1016/j.jaci.2021.08.009
250. Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A. Baricitinib: the first jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients. *Healthcare.* 2021;9(11):1575. doi:10.3390/healthcare9111575
251. Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. *JAMA Dermatol.* 2020;156(4):411–420. doi:10.1001/jamadermatol.2020.0079
252. Zainal NHM, Abas R, Mohamad Asri SF. Childhood allergy disease, early diagnosis, and the potential of salivary protein biomarkers. *Mediators Inflamm.* 2021;2021:9198249. doi:10.1155/2021/9198249
253. Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for treatment of atopic dermatitis: current status and future prospect. *J Allergy Clin Immunol Pract.* 2021;9(3):1053–1065. doi:10.1016/j.jaip.2020.11.034
254. Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. *J Am Acad Dermatol.* 2021;84(4):1059–1067. doi:10.1016/j.jaad.2020.10.085
255. Denison MS, Faber SC. And now for something completely different: diversity in ligand-dependent activation of ah receptor responses. *Curr Opin Toxicol.* 2017;2:124–131. doi:10.1016/j.cotox.2017.01.006
256. Clowry J, Irvine AD, McLoughlin RM. Next-generation anti-Staphylococcus aureus vaccines: a potential new therapeutic option for atopic dermatitis? *J Allergy Clin Immunol.* 2019;143(1):78–81. doi:10.1016/j.jaci.2018.08.038
257. Darlenski R, Kozyrskyj AL, Fluhr JW, Caraballo L. Association between barrier impairment and skin microbiota in atopic dermatitis from a global perspective: unmet needs and open questions. *J Allergy Clin Immunol.* 2021;148(6):1387–1393. doi:10.1016/j.jaci.2021.10.002

Journal of Asthma and Allergy

Dovepress

## Publish your work in this journal

The Journal of Asthma and Allergy is an international, peer-reviewed open-access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-asthma-and-allergy-journal>